Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490575 | 0.92 | HRH3 (1.00) | HRH3KMT2AMEN1 | |
| SCHEMBL4496386 | 0.92 | HRH3 (0.84) | HRH3KMT2AMEN1 | |
| SCHEMBL4498703 | 0.91 | HRH3 (0.83) | HRH3KMT2AMEN1 | |
| SCHEMBL4500028 | 0.89 | HRH3 (0.80) | HRH3KMT2AMEN1 | |
| SCHEMBL4496409 | 0.89 | HRH3 (0.80) | HRH3KMT2AMEN1 | |
| SCHEMBL4506659 | 0.89 | HRH3 (0.80) | HRH3KMT2AMEN1CYP2D6MAPK1 | |
| SCHEMBL4509013 | 0.86 | HRH3 (1.00) | HRH3 | |
| SCHEMBL4495576 | 0.82 | HRH3 (0.70) | HRH3KMT2AMEN1 | |
| SCHEMBL4510317 | 0.82 | HRH3 (0.88) | HRH3KMT2A | |
| SCHEMBL3387972 | 0.82 | HRH3 (0.76) | HRH3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608617-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1755593-B1 | NAPHTHALENE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | MCARTHUR SILVIA G | 2007-11-15 | — | — | US | disclosed |
| US-7259158-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HOFFMAN-LA ROCHE INC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | HRH3 1/4885LMNA 1696/4885KMT2A 588/4885 |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | HRH3 1/4885LMNA 1696/4885KMT2A 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.